High Throughput Drug Screening
High Throughput Drug Screening - Related Videos
09:44
High-throughput Screening for Chemical Modulators of Post-transcriptionally Regulated Genes
0 Views •
2015
Here we describe a cell-based reporter gene assay as a valuable tool to screen chemical libraries for compounds modulating post-transcriptional control mechanisms exerted through 3’ UTR.
11:28
3D Microtissues for Injectable Regenerative Therapy and High-throughput Drug Screening
0 Views •
Cited by 7 •
2017
This protocol describes the fabrication of elastic 3D macroporous microcryogels by integrating microfabrication with cryogelation technology. Upon loading with cells, 3D microtissues are generated, which can be readily injected in vivo to facilitate regenerative therapy or assembled into arrays for in vitro high-throughput drug screening.
08:05
Candida albicans Biofilm Chip (CaBChip) for High-throughput Antifungal Drug Screening
0 Views •
Cited by 9 •
2012
We have developed a high-density microarray platform consisting of 3D nano-biofilms of C. albicans called CaBChip. The susceptibility profile of drugs tested on a CaBChip is comparable to the conventional 96-well plate model, suggesting that the fungal chip is ideally suited for true high-throughput screening of antifungal drugs.
05:54
Generation of High-Throughput Three-Dimensional Tumor Spheroids for Drug Screening
0 Views •
Cited by 10 •
2018
Across a wide variety of disease indications, more physiologically relevant models are being developed and implemented into drug discovery programs. The new model system described here demonstrates how three-dimensional tumor spheroids can be cultured and screened in a high-throughput 1536-well plate-based system to search for new oncology drugs.
03:17
Cellular Bioluminescence Based Assay: A High Throughput Method for Combinatorial Drug Screening
0 Views •
2023
In this video, we describe a method highlighting the utility of bioluminescence assay for sensitive and rapid screening of drugs. These drugs can be tested alone or in combination to assess the synergism in their mode of action.
FAQs
Miniaturized assay formats reduce the scale of each test, allowing many chemical compounds or biological candidates to be evaluated in parallel. Automated liquid handling and robotics coordinate sample transfer across plate-based assays, while detection systems generate comparable readouts. Together, these components increase screening speed and help manage large libraries before candidates advance to more focused experiments.
Controls provide reference conditions for interpreting whether an assay responds as expected, while quantitative readouts convert assay behavior into measurable results. Their combination helps distinguish meaningful activity from uninterpretable results and supports consistent hit identification across many tested candidates. This evidence is important when selecting compounds for dose-response studies and mechanism testing.
The design of an engineered assay system determines how a defined target, pathway, or cell-based response is represented during testing. Linking that system with scalable analysis allows researchers to examine biological activity in a controlled, repeatable format. In bioengineering, this connection supports the evaluation of therapeutics, biomaterials, and other biologically active molecules using assay outputs suited to the research question.
Initial screening rapidly identifies hits from a large library, whereas later validation examines selected candidates in greater detail. The overview specifically places dose-response studies and mechanism testing after hit identification. This staged process uses broad screening to prioritize candidates first, then applies more focused experiments to determine whether their activity merits further development.
A typical workflow begins by assembling a library of chemical compounds or biological candidates and selecting a defined target, pathway, or cell-based assay. Automated handling distributes candidates and controls into miniaturized plate-based formats, followed by detection and quantitative analysis. Results then identify hits that can proceed to dose-response studies, mechanism testing, and additional development.
Scalable screening depends on automated liquid handling, robotics, miniaturized assay formats, and plate-based detection. These components work together to transfer candidates consistently, test many conditions in parallel, and capture quantitative assay outputs. Controls are incorporated into the testing design so that measured activity can be interpreted when ranking candidates for follow-up experiments.
This approach is useful when researchers need to examine large libraries while developing therapeutics, biomaterials, or biologically active molecules. Bioengineering contributes engineered assay systems that connect biological questions with scalable measurements. The resulting screen can shorten early-stage evaluation and help prioritize candidates before more detailed dose-response and mechanism studies.
The primary outcome is a set of identified hits showing activity against the selected target, pathway, or cell-based assay. Quantitative readouts support comparison among candidates and guide prioritization for subsequent testing. The screen does not replace dose-response or mechanism studies; instead, it supplies an early evidence base for deciding which candidates should receive those evaluations.